Business
Notice of Results and Investor Presentation
Sareum Holdings PLC will announce its financial results for the year ended June 30, 2025, on Thursday, October 23, 2025. The company will also host a live investor presentation on the same day at 14:00 BST via the Investor Meet Company platform. The presentation is open to all existing and potential shareholders, who can submit questions in advance until October 22, 2025, at 09:00 BST, or during the live presentation. A copy of the presentation will be available on the company's website following the event. Disclaimer*
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n\n \nSareum Holdings PLC\n \n(\"Sareum\" or the \"Company\")\n \nNotice of Final Results for the Year Ended 30 June 2025 and Investor Presentation\n \nCambridge, UK, 7 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, will announce its financial results for the year ended 30 June 2025 on Thursday, 23 October 2025.\nThe Company will also be holding a live presentation to investors on Thursday, 23 October 2025 at 14:00 BST via the Investor Meet Company platform.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 22 October 2025, 09:00 BST, or at any time during the live presentation.\n \nInvestors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor\nInvestors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.\nA copy of the presentation will be made available on the Company's website following the presentation.\n \n- Ends -\n \nFor further information: \n \n\n\n\n\nSareum Holdings plc\nStephen Parker, Executive Chairman\n\n\n \n01223 497700\[email protected]\n\n\n\n\nStrand Hanson Limited (Nominated Adviser)\nJames Dance / James Bellman\n \n\n\n \n020 7409 3494\n\n\n\n\nOberon Capital (Broker)\nMike Seabrook / Nick Lovering\n \n\n\n \n020 3179 5300\n\n\n\n\nICR Healthcare (Financial PR)\nJessica Hodgson / Davide Salvi\n\n\n \n020 3709 5700\n\n\n\n\n \n \nAbout Sareum\nSareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.\nThe Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.\nSareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy, and has recently initiated a prec...